The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
@Bushmaster
Yes mate, very good news. I'm very glad to invest my money in this company.
Tomorrow RNS
MGC Pharmaceuticals Ltd (ASX, LSE: MXC, ‘MGC Pharma’ or ‘the Company’), a European based
bio-pharma company specialising in the production and development of phytocannabinoid-derived
medicines, is pleased to announce its ongoing pre-clinical research program (‘Study’) into
Glioblastoma Multiforme (‘GBM’), has significantly progressed and has now been expanded to
explore the use of nano technology in relation to the most effective treatment delivery systems.
GBM is the most aggressive and, to date, therapeutically resistant primary brain tumour.
This important GBM research program is being conducted in collaboration with MGC Pharma, the
National Institute of Biology (‘NIB’) and the Neurosurgery Department at the University Medical
Centre in Ljubljana, Slovenia. It is focused on testing cannabinoid formulations on fresh
glioblastoma tumour tissues, obtained from patients after surgical removal of the tumour, to
determine the optimal cannabinoid preparation for the effective treatment of the remaining
cancer. The program tests cannabinoids alone and in combination with chemotherapeutic
temozolomide.
The objective of the pre-clinical in-vitro research is to develop novel formulations to define the
clinical protocols for clinical trials for the treatment of high-grade brain tumours with cannabinoids.
The Study has now been expanded to include testing the effect of both cannabidiol (‘CBD’) and
cannabigerol (‘CBG’) on tumour cells when delivered via a nanoparticle delivery system. Successful
results of this testing would potentially lead to a significant breakthrough in the treatment of brain
cancer through oral administration (rather than invasive treatments). Nanoparticles are believed to
improve the bioavailability and the blood to brain barrier issues, which are being optimised using
SNEDD (Self Nano-Emulsifying Drug Delivery).
I think we need to compare MGC with GWP.
GWP Development Pipeline:
CBDV (GWP42006)
1. This is a homologue of cannabidiol currently being developed for the treatment of epilepsy and autism spectrum disorders. It has a very slightly different chemical structure to the original molecule but has been shown to posses similar properties. It is also a non-psychoactive cannabinoid. It is currently in the initial stages of development, but has so far shown promising results. ( Epilepsy / Autism Spectrum Disorders both are in phase 2)
2. In addition, we have a number of other products at various stages in the development pipeline. These include GWP42003 IV for Neonatal Hypoxic-Ischemic Encephalopathy, GWP42002/GWP42003 for Glioblastoma, and GWP42003 for Schizophrenia. ( Neonatal Hypoxic-Ischemic Encephalopathy / Glioblastoma / Schizophrenia )
*********************
MGC Development Pipeline:
1. CANNEPIL® – DESIGNED FOR TREATMENT OF REFRACTORY EPILEPSY
Phase IIb Clinical Trial at Schneider Hospital in Israel on the safety and efficacy of CannEpil® as an add on treatment in children and adolescents with refractory epilepsy
A controlled trial with the Swinburne University of Technology, Melbourne to assess the effect of CannEpil® on driving performance
2. COGNICANN® - DESIGNED FOR TREATMENT OF DEMENTIA AND ALZHEIMER’S DISEASE
Phase II Clinical Trial with the University of Notre Dame in Perth, WA to evaluate the potential behavioral benefits CogniCann®may have on patients with dementia and Alzheimer’s disease
3. ARTEMIC – DESIGNED FOR TREATMENT OF COVID-19
Phase II Clinical Trial on ArtemiC is designed to target viral infections with inflammatory complications, and currently, the safety and efficacy are being evaluated on COVID-19 infected patients. Trials are currently being undertaken at Nazareth Hospital EMMS and Hillel Yaffe Hospital in Israel, and Mahatma Gandhi Mission’s Medical College & Hospital, India
**********************
So if we look at these pipelines for these 2 companies, we can see they are not the same as other cannabis companies such as Canabo, Aphria, Aurora which they making CBD oil for vape.
@nige0966
English is not my first language. Hope you getting my point about the company
I don't know why they put them under cannabis company. This company is a medical company they don't make any CBD oil so people can just walking to the shops and buy one. They use cannabis to make a medicine which will use in hospitals or only doctors can give to patients. They revenue would be deffirent with cannabis companies which they selling the CBD oil. Please correct me if you think I'm wrong on this
Here you go
https://youtu.be/qikchrfhkho
Another video to watch
https://youtu.be/itKwpRlACB0
I find it thanks mate
Guys where can I find the video for this morning? Thanks
Swiss PharmaCan and its Australia-based study partner, MGC Pharma, have announced that phase II testing of the potential anti-COVID drug ArtemiC has produced promising results, showing a statistically significant improvement in the clinical recovery of COVID-19 patients versus a placebo group.
None of the subjects treated with ArtemiC required supplemental oxygen, mechanical ventilation or intensive care. In contrast, these interventions were necessary for 23.4 percent of patients in the placebo group. The study involved 50 infected patients at three independent hospitals in Israel and met all of the COVID-19 study requirements of the North American regulatory authority, the FDA.
ArtemiC is a drug candidate based on Swiss PharmaCan’s innovative, licensed technology. It imitates the same molecular encapsulation process that the human body uses to absorb liposoluble molecules, called micellization. Swiss PharmaCan explains on its website: “We can now achieve results that were once thought impossible – and we do it using only natural products.”
According to the press release, the phase II results open up market opportunities for a variety of illnesses that are associated with a potentially fatal cytokine storm, as is COVID-19. This includes influenza, autoimmune diseases, inflammatory gastrointestinal disorders, and the effects of chemotherapy. Consequently, the phase III study is expected to be an international, multicenter study involving 250 patients with a broad spectrum of inflammatory indications for the use of ArtemiC. It is anticipated to take place in Brazil in the first half of 2021.
Good to listen to this (11/02/2021)
https://www.***************************/afc-energy,-the-right-technology-at-the-right-time-analyst-interview/412960471
Don't mix up this company with other CBD oil companies.
Swiss PharmaCan and its Australia-based study partner, MGC Pharma, have announced that phase II testing of the potential anti-COVID drug ArtemiC has produced promising results, showing a statistically significant improvement in the clinical recovery of COVID-19 patients versus a placebo group.
None of the subjects treated with ArtemiC required supplemental oxygen, mechanical ventilation or intensive care. In contrast, these interventions were necessary for 23.4 percent of patients in the placebo group. The study involved 50 infected patients at three independent hospitals in Israel and met all of the COVID-19 study requirements of the North American regulatory authority, the FDA.
ArtemiC is a drug candidate based on Swiss PharmaCan’s innovative, licensed technology. It imitates the same molecular encapsulation process that the human body uses to absorb liposoluble molecules, called micellization. Swiss PharmaCan explains on its website: “We can now achieve results that were once thought impossible – and we do it using only natural products.”
According to the press release, the phase II results open up market opportunities for a variety of illnesses that are associated with a potentially fatal cytokine storm, as is COVID-19. This includes influenza, autoimmune diseases, inflammatory gastrointestinal disorders, and the effects of chemotherapy. Consequently, the phase III study is expected to be an international, multicenter study involving 250 patients with a broad spectrum of inflammatory indications for the use of ArtemiC. It is anticipated to take place in Brazil in the first half of 2021.
I can't buy any on T212?